VERAXA Biotech AG (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer, effective immediately. Erkel, previously vice president of research and development at the company, will lead advancement of VERAXA’s proprietary BiTAC(R) platform technologies for the development of cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart following a transition period.
Erkel brings two decades of experience in antibody therapeutics, antibody engineering and preclinical development, including prior leadership roles at MorphoSys AG, where he led immuno-oncology programs focused on T-cell engagers. VERAXA said his experience managing multidisciplinary research programs will support efforts to expand the company’s oncology pipeline and advance BiTAC(R) candidates toward clinical development.
The appointment comes as VERAXA focuses on advancing its pipeline of bispecific T cell engagers, bispecific ADCs and other innovative antibody-based formats. The company’s BiTAC platform is designed to target solid tumors, a challenging area in oncology where treatment options remain limited. The move signals VERAXA’s commitment to accelerating its research and development efforts, with the aim of bringing new therapies to patients.
For more details, the full press release is available at https://nnw.fm/cR1RS. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company’s newsroom provides latest updates at https://ibn.fm/VRXA.
This leadership change underscores VERAXA’s strategy to strengthen its scientific team as it progresses its pipeline. Investors and industry watchers will be looking for updates on clinical development timelines for BiTAC candidates. The company’s forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, involve risks and uncertainties that could cause actual results to differ materially.
